Nektar Therapeutics EV/EBIT NKTR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 6.7×; Aug 2019
Peer median: 9.9×

Nektar Therapeutics has no meaningful EV/EBIT today: it made an operating loss of $140.7M over the last twelve months.

It was last meaningful in Aug 2019, at 6.7×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2019	6.7×	6.2×	8.9×
2018	6.1×	5.1×	10.6×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	39.7×	23.3×	46.1×

Against its peers

Companies in Drug Manufacturers - General nearest Nektar Therapeutics' size, closest first, today.

Company	EV/EBIT
NKTRNektar Therapeutics	n/m
OMEROmeros	n/m
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
AMPHAmphastar Pharmaceuticals	12.2×
PAHCPhibro Animal Health	11.7×
ANIPANI Pharmaceuticals	10.5×
ABUSArbutus Biopharma	4.9×
HRMYHarmony Biosciences	6.9×
COLLCollegium Pharmaceutical	9.4×
PBHPrestige Consumer Healthcare	14.5×
Peer median	9.9×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Nektar Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.